T
23.75
1.01 (4.42%)
| Previous Close | 22.74 |
| Volume | 2,187,458 |
| Price / Sales | 54.04 |
| Price / Book | 3.93 |
| 52 Weeks Range |
| Operating Margin (TTM) | -788.76% |
| Diluted EPS (TTM) | -1.20 |
| Quarterly Revenue Growth (YOY) | -16.70% |
| Total Debt/Equity (MRQ) | 22.16% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -135.34 M |
| Levered Free Cash Flow (TTM) | -67.25 M |
| Return on Assets (TTM) | -26.79% |
| Return on Equity (TTM) | -61.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Tango Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | -0.7 |
| AI Technical info | NA |
| Technical Oscillators info | -0.5 |
| Technical Moving Averages info | -1.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | 0.0 |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.5% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | 0.7 |
| Final Score | -0.30 |
Select this tab to load the latest available analysis.
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.59% |
| % Held by Institutions | 97.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp Iv, Llc | 30 Jun 2026 | 6,374,574 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CRYSTAL ADAM | - | 21.76 | -5,000 | -108,800 |
| NEWCOMB JESSICA | - | 21.76 | -7,031 | -152,995 |
| Aggregate Net Quantity | -12,031 | |||
| Aggregate Net Value ($) | -261,795 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 21.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NEWCOMB JESSICA | Officer | 02 Nov 2026 | Automatic sell (-) | 7,031 | 21.76 | 152,995 |
| CRYSTAL ADAM | Officer | 02 Nov 2026 | Automatic sell (-) | 5,000 | 21.76 | 108,800 |
| CRYSTAL ADAM | Officer | 02 Nov 2026 | Option execute | 5,000 | - | - |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |